RxDoctor Payments Data

Lee Davis, MD

Interventional Cardiology · White Hall, ARNPI 1144269978

Payments from drug & device makers

$2,893in general payments, 2019–2025

Across 109 payments — averaging $26.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$1K
  • Abbott$410
  • Merck$303
  • Novartis$172
  • Johnson & Johnson$136
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$105
  • plus $484 from 14 others

What the payments were for

  • Food & beverage$2,893100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,893 in reported general payments places this provider in the 20th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$265,474
Medicare patients
247
Services billed
4,670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan167$157,099
EliquisApixaban126$96,144
BrilintaTicagrelor89$49,762
XareltoRivaroxaban43$30,449
FarxigaDapagliflozin Propanediol23$18,969
Hydralazine Hcl200$3,765
Prasugrel Hcl16$3,491
Ranolazine ErRanolazine54$2,979
Metoprolol Tartrate438$2,440
Atorvastatin Calcium272$2,409
Amlodipine Besylate419$2,251
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide197$2,130
Potassium Chloride100$2,116
Losartan Potassium205$1,820
Nitroglycerin64$1,311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$172$157,099167 claims
PfizerEliquis$54$96,144126 claims
AstraZenecaBrilinta, Farxiga$68$68,730112 claims
Johnson & JohnsonXarelto$136$30,44943 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in White Hall

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →